TICKERNERD
Menu
CLDXCLDXHealthcare · Biotechnology

CLDX Stock Forecast: Celldex Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$28
−1.47% on the day

The 15 Wall Street analysts covering Celldex Therapeutics, Inc. hold a median 12-month price target of $64 — +129.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 13 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.2B
Ticker Nerd rank
27 / 100
Median analyst target
$64
Analysts covering
15
Revenue$22K−97.0% y/y
Operating income−$80.6M
Net income−$73.5M
Free cash flow−$60.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.5%
1M
−29.0%
YTD
+2.5%
1Y
+5.2%
From 52W high
−38.0%
From 52W low
+23.3%
$23
$45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CLDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celldex Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Oct 2026
27 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Accruals
67
Momentum
62
Volatility
41
Size
34
Issuance
28
Growth
26
Quality
16
Value
14

Revisions (72): Analysts have, on balance, been raising their forecasts.

Value (14): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100Jan 26Apr 26Jul 26Oct 26CLDXHigh $100Median $64Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $28Median $64High $100

The green dot is the last close — the median target sits +129.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
2 Oct 2026HC Wainwright & Co.ReiteratesBuy$64
23 Sept 2026Leerink PartnersMaintainsOutperform$70 → $88
23 Sept 2026Leerink PartnersMaintainsOutperform—
23 Sept 2026Morgan StanleyMaintainsOverweight$50 → $57
23 Sept 2026Morgan StanleyMaintainsOverweight—
22 Sept 2026Cantor FitzgeraldMaintainsOverweight—
22 Sept 2026Cantor FitzgeraldMaintainsOverweight$61 → $72
22 Sept 2026HC Wainwright & Co.MaintainsBuy—
22 Sept 2026HC Wainwright & Co.MaintainsBuy$42 → $64
10 Sept 2026Morgan StanleyMaintainsOverweight$46 → $50
10 Sept 2026Morgan StanleyMaintainsOverweight—
7 Aug 2026BarclaysMaintainsOverweight—
7 Aug 2026BarclaysMaintainsOverweight$48 → $53
7 Aug 2026Morgan StanleyMaintainsOverweight$40 → $46
7 Aug 2026Morgan StanleyMaintainsOverweight—
29 July 2026Wells FargoMaintainsOverweight—
29 July 2026Wells FargoMaintainsOverweight$48 → $72
22 July 2026Canaccord GenuityMaintainsBuy—
22 July 2026Canaccord GenuityMaintainsBuy$62 → $60
22 July 2026Cantor FitzgeraldMaintainsOverweight$67 → $61

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CLDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Celldex Therapeutics, Inc. returned +5.2% against +17.5% for the S&P 500, dividends included.

CLDX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26CLDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CLDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Celldex Therapeutics, Inc. (CLDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.2×

Cheaper than 92% of US stocks

Price / sales
14040.9×

Cheaper than 1% of US stocks

Price / book
3.1×

Cheaper than 30% of US stocks

EV / EBITDA
−5.0×

Cheaper than 80% of US stocks

Growth & margins
Revenue growth (YoY)
−97.0%

Higher than 2% of US stocks

Earnings growth (YoY)
−97.0%

Higher than 2% of US stocks

Gross margin
—
Operating margin
−366468.2%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−43.9%

Higher than 23% of US stocks

Return on assets
−27.6%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Celldex Therapeutics, Inc. (CLDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Celldex Therapeutics, Inc. has a market value of $2.2B and an enterprise value of $1.6B.

  • Revenue in the twelve months to 30 June 2026: $158K. The latest quarter shrank 97.0% year on year.

  • Net income over the same four quarters: −$300.5M, a −190220.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−4.35.

  • Free cash flow in the twelve months to 30 June 2026: −$242.1M.

  • Shares outstanding: 78.5M.

  • Trailing P/E: −7.2×; forward P/E: −6.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Celldex Therapeutics, Inc. employs 198 people — $798.0 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

CLDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLDXCelldex Therapeutics, Inc.$2.2B
27
AUPHAurinia Pharmaceuticals, Inc.$2.2B
93
HRMYHarmony Biosciences Holdings, Inc.$2.1B
88
IRONDisc Medicine, Inc.$2.1B
33
NVAXNovavax, Inc.$2.1B
61
NRIXNurix Therapeutics, Inc.$2.2B
93
PHVSPharvaris NV$2.1B
39

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Celldex Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLDX news & analysis

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)

PRNewsWire · 12 Oct 2026negative

Purcell & Lefkowitz LLP said it is investigating Celldex Therapeutics on behalf of shareholders to determine whether directors breached fiduciary duties in connection with recent corporate actions.

Why it matters — The investigation concerns the conduct of Celldex’s directors and may be relevant to shareholders monitoring the company’s recent corporate actions.

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Seeking Alpha · 22 Sept 2026positive

Celldex Therapeutics held a discussion regarding positive Phase 3 results for barzolvolimab in chronic spontaneous urticaria, as reported by Seeking Alpha. The item is a transcript of the company discussing these results.

Why it matters — CLDX watchers would care because the positive Phase 3 results for barzolvolimab represent a potentially significant milestone for one of the company's key development programs.

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Benzinga · 22 Sept 2026neutral

Celldex Therapeutics shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating barzolvolimab for chronic spontaneous urticaria (CSU) in patients with inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.

Why it matters — A CLDX watcher would care because these Phase 3 topline results for barzolvolimab represent a key clinical milestone for the company's lead candidate in treating chronic spontaneous urticaria.

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

MarketBeat · 22 Sept 2026positive

Celldx Therapeutics reported positive top-line results from its two Phase III EMBARQ-CSU studies of barzolvolimab in adults with chronic spontaneous urticaria who remained symptomatic despite H1 antihistamine treatment. Both evaluated dose regimens met the primary endpoint and all key secondary endpoints, with efficacy sustained or deepening through 24 weeks.

Why it matters — These successful Phase III results for barzolvolimab represent a significant clinical advancement for a key product in Celldx's pipeline.

4 Biotech Stocks With Key Clinical Readouts Expected This Fall

Zacks Investment Research · 22 Sept 2026neutral

Zacks Investment Research reports that Celldex Therapeutics (CLDX), along with KOD, RAPP and PCVX, faces key clinical readouts this fall that could influence their drug and vaccine pipelines.

Why it matters — CLDX watchers would care because upcoming clinical readouts this fall could shape the outlook for the company's drug pipeline.

FAQ

Frequently asked questions about CLDX stock

What is the CLDX stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Celldex Therapeutics, Inc. have a median 12-month price target of $64, with estimates ranging from $28 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CLDX stock a buy right now?

Of the 15 analysts covering Celldex Therapeutics, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celldex Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 13 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CLDX?

As at 13 Oct 2026, Celldex Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will CLDX stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +129.9% from the last close, and Ticker Nerd's factor model ranks Celldex Therapeutics, Inc. 27 out of 100 as at 13 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CLDX stock forecast for 2030?

No analyst covering Celldex Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $100 over the next 12 months.

How has CLDX stock performed over the past year?

Celldex Therapeutics, Inc. returned +5.2% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celldex Therapeutics, Inc. do?

Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.

What is the latest news on CLDX?

The most recent item we track (PRNewsWire, 12 Oct 2026): "SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Celldex Therapeutics, Inc. (NASDAQ: CLDX)". Purcell & Lefkowitz LLP said it is investigating Celldex Therapeutics on behalf of shareholders to determine whether directors breached fiduciary duties in connection with recent corporate actions.

Company

About Celldex Therapeutics, Inc.

Celldex Therapeutics Inc. is a biopharmaceutical company focused on developing antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases. The company’s current programs center on monoclonal and bispecific antibodies designed to modulate mast cell biology and other immune pathways associated with chronic conditions that have limited treatment options. Its lead clinical assets include barzolvolimab, a KIT-targeting antibody being studied across several mast cell–driven disorders, and CDX-622, a bispecific candidate aimed at key inflammatory mechanisms. Celldex Therapeutics Inc. operates in the biotechnology sector and concentrates on advancing immunology-focused therapies through clinical development for patients with significant unmet medical needs. Headquartered in Hampton, New Jersey, the company is known for its specialized pipeline rather than a broad commercial product portfolio.

CEO Mr. Anthony S. Marucci M.B.A. · 198 employees · United States · https://www.celldex.com